Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

This study has been completed.
OSI Pharmaceuticals
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: July 4, 2007
Last updated: July 8, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):